Pirtobrutinib Shows Promise for Previously Treated CLL, SLL
Photo by Paweł Czerwiński on Unsplash

Pirtobrutinib Shows Promise for Previously Treated CLL, SLL

The 2021 Society for Hematological Oncology (SOHO) Annual Meeting took place last month from September 8-11, 2021. During the meeting, researchers discussed new advances in the field of hematology. According…

Continue Reading Pirtobrutinib Shows Promise for Previously Treated CLL, SLL
The FDA Grants Orphan Drug Designation to Oncternal Therapeutics for the Treatment of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
source: pixabay.com

The FDA Grants Orphan Drug Designation to Oncternal Therapeutics for the Treatment of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

  Orphan drug designations are granted by the FDA to drugs and biologics that are developed for the treatment of rare diseases.  According to a recent article in Biospace, Oncternal…

Continue Reading The FDA Grants Orphan Drug Designation to Oncternal Therapeutics for the Treatment of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
The FDA has Approved a New Cancer Drug Called Copiktra™ (duvelisib)
qimono / Pixabay

The FDA has Approved a New Cancer Drug Called Copiktra™ (duvelisib)

The United States Food and Drug Administration has approved Copiktra™ (duvelisib). The drug is now approved as a treatment for adult patients diagnosed with refractory or relapsed chronic lymphocytic leukaemia…

Continue Reading The FDA has Approved a New Cancer Drug Called Copiktra™ (duvelisib)